2009 Publications

Research supported by Starr Cancer Consortium awards is reported in the following publications. The Starr Cancer Consortium is funded by the Starr Foundation.

Structure-Activity Analysis of Semisynthetic Nucleosomes: Mechanistic Insights into the Stimulation of Dot1L by Ubiquitylated Histone H2B.

Authors: McGinty RK, Köhn M, Chatterjee C, Chiang KP, Pratt MR, Muir TW.

ACS Chemical Biology, 2009.

The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.

Authors: Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM.

Annals of the New York Academy of Sciences, 2009.

Integrative genomic approaches to understanding cancer.

Authors: Hahn, WC; Dunn, IF; Kim, SY; Schinzel, AC; Firestein, R; Guney, I; Boehm, JS.

Biochimica et biophysica acta, 2009.

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors: Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL.

Blood, 2009.

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA).

Authors: Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen et al.

British Journal of Cancer, 2009.

AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

Authors: Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA.

Cancer Cell, 2009.

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.

Authors: Scholl C, Fröhling S., Dunn IF, Schinzel AC, Barbie DA, Kim SY, Silver SJ, Tamayo P, Wadlow RC, Ramaswamy S, Döhner K, Bullinger L, Sandy P, Boehm JS, Root DE, Jacks T, Hahn WC, Gilliland DG.

Cell, 2009.

A semisynthetic strategy to generate phosphorylated and acetylated histone H2B.

Authors: Chiang KP, Jensen MS, McGinty RK, Muir TW.

Chembiochem: A European Journal of Chemical Biology, 2009.

Regulation of DNA damage response pathways by the cullin-RING ubiquitin ligases.

Authors: Hannah, J; Zhou, PB.

DNA Repair, 2009.

The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo.

Authors: Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC.

Genes & Development, 2009.

Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts.

Authors: Levin JZ, Berger MF, Adiconis X, Rogov P, Melnikov A, Fennell T, Nusbaum C, Garraway LA, Gnirke A.

Genome Biology, 2009.

Applications of genomics in melanoma oncogene discovery.

Authors: Berger M.F., Garraway L.A.

Hematology/Oncology Clinics of North America, 2009.

Direct Bre1-Paf1 complex interactions and RING finger-independent Bre1-Rad6 interactions mediate histone H2B ubiquitylation in yeast.

Authors: Kim J, Roeder RG.

The Journal of Biological Chemistry, 2009.  

Priming of protective T cell responses against virus-induced tumors in mice with human immune system components.


Authors: Strowig T, G. C., Ploss A, Liu YF, Arrey F, Sashihara J, Koo G, Rice CM, Young JW, Chadburn A, Cohen JI, Münz C.

The Journal of Experimental Medicine, 2009.

CUL4A abrogation augments DNA damage response and protection against skin carcinogenesis.

Authors: Liu L, L. S., Zhang J, Peters SB, Hannah J, Zhang Y, Yin Y, Koff A, Ma L, Zhou P.

Molecular Cell, 2009.

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors: Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, Fröhling S, Chan EM, Sos ML, Michel K, Mermel C, Silver SJ, Weir BA, Reiling JH, Sheng Q, Gupta PB, Wadlow RC, Le H, Hoersch S, Wittner BS, Ramaswamy S, Livingston DM, Sabatini DM, Meyerson M, Thomas RK, Lander ES, Mesirov JP, Root DE, Gilliland DG, Jacks T, Hahn WC.

Nature, 2009.

Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger.


Authors: Wang GG, Song J, Wang Z, Dormann HL, Casadio F, Li H, Luo JL, Patel DJ, Allis CD. 

Nature, 2009.

Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes.

Authors: Wang Y, Juranek S, Li H, Sheng G, Wardle GS, Tuschl T, Patel DJ.

Nature, 2009.

WSTF regulates the H2A.X DNA damage response via a novel tyrosine kinase activity.

Authors: Xiao A, L. H., Shechter D, Ahn SH, Fabrizio LA, Erdjument-Bromage H, Ishibe-Murakami S, Wang B, Tempst P, Hofmann K, Patel DJ, Elledge SJ, Allis CD.

Nature, 2009.

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Authors: Kilpivaara O, M. S., Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL.

Nature Genetics, 2009.
MEK1 mutations confer resistance to MEK and B-RAF inhibition.

Authors: Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA.

Proceedings of the National Academy of Sciences of the USA, 2009.

A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4.

Authors: Lee J, K. D., Lee S, Yang QH, Lee DK, Lee SK, Roeder RG, Lee JW.

Proceedings of the National Academy of Sciences of the USA, 2009.
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Authors: Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N.

Proceedings of the National Academy of Sciences of the USA, 2009.